Artia Global Partners LP Takes $476,000 Position in Kodiak Sciences Inc. $KOD

Artia Global Partners LP purchased a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the fourth quarter, HoldingsChannel reports. The firm purchased 17,019 shares of the company’s stock, valued at approximately $476,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Balyasny Asset Management L.P. boosted its stake in shares of Kodiak Sciences by 1,607.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 263,278 shares of the company’s stock worth $7,361,000 after buying an additional 247,859 shares during the last quarter. Baker BROS. Advisors LP boosted its stake in shares of Kodiak Sciences by 15.1% in the 4th quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company’s stock worth $556,940,000 after buying an additional 2,608,696 shares during the last quarter. Boothbay Fund Management LLC boosted its stake in shares of Kodiak Sciences by 48.8% in the 4th quarter. Boothbay Fund Management LLC now owns 173,221 shares of the company’s stock worth $4,843,000 after buying an additional 56,786 shares during the last quarter. J. Goldman & Co LP purchased a new position in shares of Kodiak Sciences in the 4th quarter worth $809,000. Finally, AQR Capital Management LLC boosted its stake in shares of Kodiak Sciences by 40.1% in the 4th quarter. AQR Capital Management LLC now owns 57,693 shares of the company’s stock worth $1,613,000 after buying an additional 16,520 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Kodiak Sciences Price Performance

Shares of KOD stock opened at $35.71 on Thursday. Kodiak Sciences Inc. has a 1 year low of $3.43 and a 1 year high of $47.84. The firm has a fifty day moving average price of $38.95 and a 200-day moving average price of $30.89. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -8.56 and a beta of 2.21.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.01). Equities research analysts expect that Kodiak Sciences Inc. will post -3.89 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KOD. UBS Group raised their price target on Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. HC Wainwright restated a “buy” rating and issued a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $14.00 to $61.00 in a research note on Monday, May 11th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $42.14.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.